We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Merck and Co Inc | NYSE:MRK | NYSE | Common Stock |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
-0.79 | -0.62% | 127.47 | 128.48 | 127.18 | 128.11 | 6,221,929 | 01:00:00 |
By Neetha Mahadevan
FRANKFURT--German pharmaceutical company Merck KGaA on Monday said it would acquire U.S. firm Sigma-Aldrich Corp. for $17 billion, as it bids to strengthen its position in the life science industry.
Merck will acquire all of Sigma-Aldrich for $140 a share in cash, a 37% premium to Sigma's closing share price on Friday. The acquisition, the largest in Merck's history, represents "a quantum leap" for its life sciences business and increases its presence in North America and Asia, Chief Executive Karl-Ludwig Kley said.
Shares of Merck rose as investors bet the move would make the company one of the leading players in the $130 billion global life science industry.
"This looks like a very strategic deal and, at first glance, it makes a lot of sense--even if the size of the deal is surprising," Warburg analyst Ulrich Huwald said, adding that the companies have complementary segments and the deal will increase Merck's value.
St. Louis-based Sigma-Aldrich specializes in products used in scientific research and development in fields from biotechnology to pharmaceuticals. It also manufactures high-technology materials for smartphones and TV screens.
Monday's deal is the latest in a string of transactions in the pharmaceutical industry, which has seen a surge in M&A activity this year. AbbVie Inc. agreed to pay $54 billion for Shire PLC, while GlaxoSmithKline PLC and Novartis AG agreed to swap some businesses in a deal worth more than $20 billion. Last week, Bayer AG said it would shed its plastics business to focus on life science, after it bought Merck & Co.'s consumer-product business for $14.2 billion earlier this year.
Merck KGaA is not affiliated with Merck & Co. of the U.S.
The Sigma-Aldrich purchase is expected to immediately boost Merck's adjusted earnings per share and operating profit margin. Merck expects annual synergies of about EUR260 million, which should be fully achieved within three years after closing. It also expects integration costs of about EUR400 million spread over 2015 to 2018.
Merck's divisions include its biopharmaceuticals division, Merck Serono, consumer health division, high-tech chemicals unit, Performance Materials, and Merck Millipore. Sigma-Aldrich will become part of Millipore, which accounts for about 25% of the company's annual revenue.
Merck has already secured bridge financing for the all-cash deal and expects it to close midyear 2015, pending regulatory approvals. The acquisition has been unanimously approved by Sigma-Aldrich's board of directors and will be presented to Sigma-Aldrich's shareholders for approval at a special meeting.
Sigma-Aldrich has delivered consistent results in recent years, with revenue and profit often meeting or exceeding analysts' expectations. In its most recent period, the company posted $701 million in sales, up 2.9% over the prior-year period, while the bottom line jumped 12%, driven by growth in the U.S. research market.
Michael Calia
and
Natalia Drozdiak
contributed to this article.
Write to Neetha Mahadevan at neetha.mahadevan@wsj.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
1 Year Merck Chart |
1 Month Merck Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions